<DOC>
	<DOCNO>NCT00753740</DOCNO>
	<brief_summary>This study assess effect IT-101 delaying cancer progression patient platinum sensitive ovarian cancer .</brief_summary>
	<brief_title>Efficacy Study Maintenance IT-101 Therapy Ovarian Cancer Patients .</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Key Women age 18 78 , inclusive ; Evidence platinumsensitive ovarian cancer follow patient 's primary treatment ( &gt; = 6 month ) ; Received 2nd line platinumbased chemotherapy regimen ( 46 cycle ) without evidence progression ; May measurable unmeasurable disease ; ECOG 0 1 ; Ability understand willingness sign write informed consent document . Key Women pregnant lactating ; Prior treatment topoisomerase inhibitor ; Patients unacceptable organ and/or hematologic reserve screening ; Urine protein &gt; 500 mg/day active nephropathy ; Electrocardiogram ( ECG ) evidence clinically significant conduction abnormality active ischemia determine investigator ; History pancreatitis within last 12 month ; Patients treat previous high dose chemotherapy stem cell transplant within last 5 year ; Use investigational agent within 4 week study enrollment ; Uncontrolled intercurrent illness , include limited , ongoing active infection , psychiatric illness comorbidity present risk patient determine investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Solid Malignancies</keyword>
</DOC>